-
FAISL Stabilizes FAK in Triple-Negative Breast Cancer
2026-09-15
The reference study identifies FAISL as a long noncoding RNA that stabilizes focal adhesion kinase by preventing Calpain 2-mediated proteolysis, rather than by increasing FAK mRNA. Its cellular, patient-dataset, and mouse-model evidence connects this post-translational regulatory mechanism with TNBC adhesion, growth, survival, and metastasis, while supporting FAISL as a potential RNA-targeting opportunity.
-
Dehydroepiandrosterone (DHEA) Research Workflow
2026-09-15
Build reproducible DHEA experiments for granulosa cell proliferation, apoptosis inhibition, and neural cell survival using concentration windows matched to the biological question. A reference-study-inspired workflow adds ER-stress controls, pathway readouts, and troubleshooting guidance without confusing DHEA biology with ferulic acid evidence.
-
Nirmatrelvir: From Protease Biology to Assay Design
2026-09-14
Nirmatrelvir (PF-07321332) is more than a SARS-CoV-2 protease inhibitor: it can serve as a mechanistic anchor for separating viral entry, polyprotein processing, and replication phenotypes. This assay-centered guide connects 3CL protease biology with computational screening and practical antiviral therapeutics research.
-
Oxaliplatin Workflows for DNA Damage Research
2026-09-14
Build reproducible Oxaliplatin assays around DNA adduct formation, apoptosis, and treatment resistance rather than relying on viability alone. This guide connects cell-based dose finding with xenograft design and immune-oncology assay choices inspired by the Wnt/BCL9 reference study.
-
TH287: MTH1 Inhibition as a DNA-Damage Timing Tool
2026-09-13
TH287 is a potent MTH1 inhibitor that converts oxidized nucleotide stress into a measurable DNA-damage phenotype. This article goes beyond radiosensitization summaries to show how treatment sequence, orthogonal readouts, and formulation controls can improve cancer research assays.
-
mCherry mRNA for Kidney-Targeted Assays
2026-09-12
Use mCherry mRNA as a bright, transient benchmark for transfection, nanoparticle loading, uptake, and protein expression. This workflow combines Cap 1 chemistry and modified nucleotides with orthogonal fluorescence, qPCR, cytotoxicity, and particle-quality measurements.
-
FAISL–FAK Control of TNBC Progression and Metastasis
2026-09-12
The reference study identifies FAISL as a long noncoding RNA that stabilizes focal adhesion kinase by preventing Calpain 2-mediated proteolysis, thereby strengthening malignant adhesion, survival, and metastatic behavior in triple-negative breast cancer. Its combination of TCGA analysis, RNA–protein interaction profiling, mechanistic cell studies, patient-data correlation, and reduction-responsive siRNA delivery reveals a regulatory strategy beyond direct FAK kinase inhibition.
-
Phenothiazines, ROS, and Macrophage Antibacterial Activity
2026-09-11
Qiu et al. show that phenothiazines strengthen macrophage control of intracellular bacteria through coordinated increases in reactive oxygen species, lysosomal activity, and autophagy. The study supports a host-directed antibacterial strategy, while its inhibitor and scavenger experiments also define important limits for translating this mechanism to individual phenothiazine compounds.
-
DPP8/9–CARD8 Inflammasome in Resting Lymphocytes
2026-09-11
Johnson and colleagues show that DPP8/9 inhibitors can trigger CARD8-dependent pyroptosis in resting human and rodent lymphocytes, extending inflammasome biology beyond myeloid cells. The study identifies resting CD4+ and CD8+ T cells as particularly responsive while revealing a marked resistance of activated human T cells, providing a framework for investigating cell-state-specific inflammatory death.
-
CD36 Lipid Signaling Drives Immune Escape in AML
2026-09-10
A 2024 Cell Reports Medicine study identifies a non-canonical CD36 lipid-signaling program that enables AML cells to suppress T-cell activity and reduce the effectiveness of decitabine. The work separates this immune mechanism from lipid oxidation and supports lipid restriction with statins as a strategy for improving hypomethylating-agent responses in experimental AML models.
-
Resazurin Sodium Salt for Translational iPSC Assays
2026-09-10
A mechanistic and strategic guide to using Resazurin sodium salt as a metabolic context readout alongside functional iPSC-derived airway models, with practical controls, translational limitations, and workflow recommendations for CF drug development.
-
Measuring Drug Responses in Cancer More Precisely
2026-09-09
Hannah R. Schwartz’s dissertation shows why relative viability and fractional viability should not be treated as interchangeable measures of anticancer activity. Its central contribution is a response framework that separates growth inhibition from cell killing while accounting for their different proportions and timing, improving interpretation of in vitro drug-response experiments.
-
FAISL Stabilizes FAK in Triple-Negative Breast Cancer
2026-09-09
The reference study identifies FAISL as a long noncoding RNA that stabilizes focal adhesion kinase (FAK) by preventing Calpain 2-mediated proteolysis, thereby promoting triple-negative breast cancer progression and metastasis. Its combination of transcriptomic discovery, mechanistic validation, and reduction-responsive siRNA delivery suggests a distinct way to target FAK regulation beyond direct kinase inhibition.
-
Ziprasidone HCl Workflows for Cancer and Brain Research
2026-09-08
Ziprasidone HCl supports a practical dual-domain workflow: GOT1-focused tumor metabolism studies alongside receptor-oriented neuroscience research. This guide connects concentration selection, assay controls, permeability testing, and troubleshooting to published clinical observations and product-specific handling data.
-
Cy5.5 NHS Ester for Piezo-Nanoplatform Imaging
2026-09-08
Cy5.5 NHS ester (non-sulfonated) converts amine-bearing proteins, peptides, and modified oligonucleotides into trackable near-infrared probes for ultrasound-responsive nanomedicine. This practical guide connects covalent labeling, in vivo fluorescence imaging, and assay controls to the biomimetic piezoelectric epilepsy platform described in the reference study.